Have any questions? 706-721-6582 or cts@augusta.edu
- A Prospective, Randomized, Double-Blind, Placebo-Controlled Phase 3 Study of VGX-3100 Delivered Intramuscularly Followed By Electroporation With Cellectra™ 5PSP For The Treatment Of HPV-16 And/Or HPV-18 Related High Grade Squamous Intraepithelial Lesion (HSIL) Of The Cervix
Clinical Trial
A Prospective, Randomized, Double-Blind, Placebo-Controlled Phase 3 Study of VGX-3100 Delivered Intramuscularly Followed By Electroporation With Cellectra™ 5PSP For The Treatment Of HPV-16 And/Or HPV-18 Related High Grade Squamous Intraepithelial Lesion (HSIL) Of The Cervix
Women age 18 years and older who have recently had an abnormal Pap smear and an abnormal cervical biopsy may be able to participate in a study of a new medication, VGX-3100. The study is double-blind and participants may receive the study medication or placebo (an inactive substance). Study participation will last approximately 88 weeks.
Eligibility Criteria
- Women age 18 and older who have recently had an abnormal Pap smear and an abnormal cervical biopsy result may be able to qualify for a treatment trial. The trial will see if a study medication, VGX3100, is able to treat the cervical abnormalities. The study will last approximately 88 weeks and will require 10 visits to the clinic plus follow-up phone calls.
RESEARCH. INNOVATION. DISCOVERY.